A.O. POZDNYAK¹, O.S. ELSUKOVA², E.A. NIKITINA²

¹Kazan State Medical Academy – Branch Campus of the FSBEI FPE RMACPE MOH Russia, Kazan

²Kirov State Medical University, Kirov, Russia

  Contact:

Nikitina Elena Aleksandrovna – Ph. D. (medicine), Associate Professor of the Department of Internal Diseases

Address: 112 K. Marx Str., Kirov, Russian Federation, 610027, tel.: +7-953-687-18-44, e-mail: nikitinae1991@mai.ru

 Objective: to study the dynamics of carbohydrate and lipid metabolism and markers of visceral obesity (VO) in patients with type 2 diabetes mellitus (T2DM) and obesity when using a fixed combination of alogliptin and pioglitazone.

Material and methods. 30 patients with T2DM and obesity were examined. Indicators of carbohydrate and lipid metabolism and markers of VO (conicity index, index of lipid products accumulation, waist circumference to height ratio) were assessed initially and over time 6 months after the start of using alogliptin 25 mg and pioglitazone 30 mg.

Results. When taking alogliptin and pioglitazone, patients with T2DM and obesity showed a compensation of fasting and postprandial hyperglycemia, an effective reduction in glycated hemoglobin and insulin resistance of peripheral tissues, and favorable changes in lipid metabolism with a positive effect on the calculated VO indices.

Conclusions. The combination of alogliptin and pioglitazone can be recommended as a reliable and safe treatment regimen for patients with T2DM and obesity with the ability to correct major cardiovascular risk factors.

Key words: type 2 diabetes mellitus, alogliptin, pioglitazone, cardiovascular risk, cardiovascular diseases.

REFERENCES

1. Dedov I.I., Shestakova M.V., Mayorov A.Yu. et al. Algorithms of specialized medical care for patients with diabetes. Sakharnyy diabet, 2023, vol. 26, no. 2S, pp. 1-157 (in Russ.). doi.org/10.14341/DM13042
2. Ostroumova O.D., Goloborodova I.V., Fomina V.M. Cardiovascular risks in patients with type 2 diabetes. Kardiovaskulyarnaya terapiya i profilaktika, 2018, vol. 17, no. 4, pp. 81-94 (in Russ.). dx.doi.org/10.15829/1728-8800-2018-4-81-94
3. Sergienko I.V., Ansheles A.A., Khalimov Yu.Sh. et al. Kardiologicheskie aspekty sakharnogo diabeta 2 tipa [Cardiological aspects of type 2 diabetes]. Moscow: Pero, 2018. 68 p.
4. Salukhov V.V., Khalimov Yu.Sh., Shustov S.B. et al. Decrease in cardiovascular risk in patients with type 2 diabetes: an overview of the main strategies and clinical studies. Sakharnyy diabet, 2018, vol. 21, no. 3, pp. 193-205 (in Russ.). doi: 10.14341/DM9570
5. Cosentino F., Grant P.J., Aboyans V., et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J, 2020, vol. 41 (2), pp. 255-323. doi: 10.1093/eurheartj/ehz486
6. De Fronzo R.A., Burant C.F., Fleck P., et al. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 Diabetes. J Clin Endocrinol Metab., 2012, vol. 97 (5), pp. 1615-1622. doi: 10.1210/jc.2011-2243
7. Mkrtumyan A.M., Belolipetskiy Ya.A. Tandem of alogliptin and pioglitazone is a new union in the fight against type 2 diabetes. Effektivnaya farmakoterapiya, 2021, vol. 17, no. 31, pp. 18-36 (in Russ.). doi: 10.33978/2307-3586-2021-17-31-18-36
8. Belik E.V., Gruzdeva O.V. Insulin resistance: unresolved issues of harm and benefit. Sibirskiy meditsinskiy zhurnal klinicheskoy i eksperimental’noy meditsiny, 2019, vol. 34, no. 34, pp. 39-48 (in Russ.). doi.org/10.29001/2073-8552-2019-34-4-39-48
9. Bosi E., Ellis G.C., Wilson C.A. et al. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. Diabetes Obes Metab, 2011, vol. 13 (12), pp. 1088-1096. doi: 10.1111/j.1463-1326.2011.01463.x.
10. Rosenstock J., Inzucchi S.E., Seufert J. et al. Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes. Diabetes Care, 2010, vol. 33 (11), pp. 2406-2408. doi: 10.2337/dc10-0159
11. Ametov A.S., P’yanykh O.P., Vovk P.S. Prospects for the use of pioglitazone in the prevention and treatment of diabetes of type 2 and its complications. Endokrinologiya: novosti, mneniya, obuchenie, 2022, vol. 11, no. 2, pp. 56-63 (in Russ.). doi: https://doi.org/10.33029/2304-9529-2022-11-2-56-63
12. Zilov A.V., Fokina A.S., Fadeev V.V. The possibility of influence on the multi -factor of the development of glycemia in diabetes of type 2 mellitus with a combined sugar -lowering drug. RMZh, 2022, vol. 1, pp. 41-45 (in Russ.).
13. Eliasson B., Möller-Goede D., Eeg-Olofsson K. et al. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetologia, 2012, vol. 55 (4), pp. 915-925. doi: 10.1007/s00125-011-2447-3.